Biopharmaceutical
Pharmaceutical
Health
Global Blood Therapeutics
$59.029876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$59.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.85 (3.19%) Today
-$0.91 (-1.53%) After Hours
Why Robinhood?
You can buy or sell GBT and other stocks, options, ETFs, and crypto commission-free!
About
Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Read More It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
CEO
Employees
171
Headquarters
South San Francisco, California
Founded
2011
Market Cap
3.38B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.01M
High Today
$60.79
Low Today
$58.23
Open Price
$58.45
Volume
251.83K
52 Week High
$62.50
52 Week Low
$30.15
Collections
Biopharmaceutical
Pharmaceutical
Health
Therapy
Biotechnology
Medical
Technology
2015 IPO
News
Seeking AlphaMay 15
Global Blood Remains On Track For Transformational Year
Shares of GBT remain conservatively valued and investors can anticipate further appreciation as this story plays out. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle cell disease. Capital Structure Price $58.02 Shares 52,232,448 Market Cap $3,030,526,632.96 Cash & Investments $591,815,000.00 Cash per share $11.33 Debt $0.00 Enterprise Value $2,438,711,632.96 Est. Q. Cash Burn $40,000,000.00 Est. Cash Runway (...
Yahoo FinanceMay 10
Global Blood Reports Narrower-Than-Expected Loss in Q1
Global Blood Therapeutics, Inc. GBT incurred a loss of 87 cents in the first quarter of 2019, which was in line with the loss incurred in the year-ago quarter but narrower than the Zacks Consensus Estimate of a loss of 94 cents. Research and development (R&D) expenses in the first quarter were $34.5 million, up 17.8% year over year. The increase in R&D expenses was mainly due to increased employee-related costs, including non-cash stock compensation, and increased consulting spend associated with NDA filin...
Yahoo FinanceMay 8
When Will Global Blood Therapeutics, Inc. (NASDAQ:GBT) Breakeven?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Global Blood Therapeutics, Inc.'s (NASDAQ:GBT): Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The US$3.1b market-cap company announced a latest loss of -US$174.2m on 31 December 2018 for its most recent financial year result. Many investors are wonderin...
Price Paid on Robinhood
33% Higher
Right Now
52 Week Low
$30.15
Average Price Paid
$44.50
52 Week High
$62.50
Earnings
-$0.94
-$0.83
-$0.72
-$0.61
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 1, After Hours